Shionogi's Phase III trial of constipation drug naldemedine meets primary endpoint
Japanese pharmaceutical firm Shionogi has reported positive results from its Phase III trial (COMPOSE I) of naldemedine, an investigational peripherally acting mu-opioid receptor antagonist (PAMORA), to treat opioid-induced constipation (OIC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Constipation | Pharmaceuticals